Showing results (1-10 of 277) with videos related to
Sort By:
Pageof 28
Expert Opinion on Biological Therapy|July 11, 2008
Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumorsD Ross CamidgeClinical Advances in Hematology & Oncology : H&O|February 13, 2015
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignoreD Ross CamidgeClinical Lung Cancer|August 8, 2007
The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancerD Ross CamidgeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2019
Detection of NRG1 Fusions in Solid Tumors: Rare Gold?Anastasios Dimou, D Ross CamidgeJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2024
Lung Cancer Oncogene-Directed Therapy, Fertility, and PregnancyEmily Simons, D Ross CamidgeLung Cancer (Amsterdam, Netherlands)|October 1, 2018
Antibody drug conjugates in thoracic malignanciesJose M Pacheco, D Ross CamidgeNature Reviews. Clinical Oncology|April 5, 2012
Treating ALK-positive lung cancer--early successes and future challengesD Ross Camidge, Robert C DoebeleTranslational Lung Cancer Research|December 3, 2015
PROFILE 1014: lessons for the new era of lung cancer clinical researchSinead A Noonan, D Ross CamidgeCell|October 16, 2020
Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung CancerD Ross Camidge, Erin L SchenkJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2017
Reviewing RECIST in the Era of Prolonged and Targeted TherapyRustain L Morgan, D Ross CamidgePageof 28